

Enamine's IDD Platform Accelerates Nuclide Therapeutics' Precision Radiotheranostics Pipeline Towards the Clinic

Nuclide Therapeutics Leverages Enamine's Deep Expertise in Rapid and Scalable Synthesis of Small Molecules

KYIV, UKRAINE, April 2, 2026

[/EINPresswire.com/](https://EINPresswire.com/) -- Nuclide

Therapeutics and Enamine initiated their cooperation in 2025. Since then, Enamine has supported Nuclide Therapeutics in progressing from preclinical evaluation towards IND-enabling studies and first-in-human clinical trials for its lead program focused on first-in-class molecular radiotherapies for therapy-resistant cancers. The relationship proved to be highly productive and innovative, delivering development milestones ahead of schedule with short development cycles and efficient use of resources.



Nuclide Therapeutics is committed to advancing a new generation of precision radiotheranostics specifically designed to overcome resistance to current cancer therapies. The collaboration between the two companies has enabled to accelerate key aspects of Nuclide Therapeutics' preclinical development through Enamine's strong expertise in synthetic chemistry. Enamine's ability to deliver high-quality materials within compressed timelines has been instrumental in supporting Nuclide Therapeutics' radiochemistry activities and progressing their program towards IND-enabling studies and first-in-human evaluation.

Enamine's deep understanding of chemical space is reflected in its REAL Space, the world's largest and most trusted collection of make-on-demand small molecules, capturing a significant share of synthetically accessible chemical space. REAL Compounds are readily synthesised through validated parallel synthesis protocols using qualified in stock building blocks.

In combination with its integrated capabilities in medicinal chemistry, synthetic chemistry, route scouting, and scale-up, alongside optimized R&D logistics, Enamine enables rapid design-make-test-analyse (DMTA) cycles and efficient production of small molecules within short timelines. Enamine Germany, based in Frankfurt, provides strong support in project coordination, rapid development, and scale-up activities.

Enamine Germany, a leading provider of chemical compounds & a scientifically driven, integrated discovery Contract Research Organisation for integrated drug discovery (IDD) with unique partnering opportunities in exploring new chemical spaces. The company combines access to the in-house produced screening compounds (4.7 million in stock) and building blocks (350,000 in stock) with a comprehensive platform of integrated discovery services in bioinformatics, medicinal chemistry, synthetic chemistry, route scouting, and scale-up. Enamine Germany, based in Frankfurt, provides strong support in project coordination, rapid development, and scale-up activities.

Enamine Germany, a leading provider of chemical compounds & a scientifically driven, integrated discovery Contract Research Organisation for integrated drug discovery (IDD) with unique partnering opportunities in exploring new chemical spaces. The company combines access to the in-house produced screening compounds (4.7 million in stock) and building blocks (350,000 in stock) with a comprehensive platform of integrated discovery services in bioinformatics, medicinal chemistry, synthetic chemistry, route scouting, and scale-up. Enamine Germany, based in Frankfurt, provides strong support in project coordination, rapid development, and scale-up activities.

Enamine Germany:

Enamine Germany is a leading provider of chemical compounds & a scientifically driven, integrated discovery Contract Research Organisation for integrated drug discovery (IDD) with unique partnering opportunities in exploring new chemical spaces.

Nuclide Therapeutics Ltd. is a pioneering clinical-stage biotech company and King's College London spin-out focused on developing targeted radiopharmaceuticals for therapy-resistant cancers.

For more information, please visit: www.nuclidetx.com

Enamine Germany

Enamine is the leading provider of chemical compounds and a scientifically driven, integrated discovery Contract Research Organisation for integrated drug discovery (IDD) with unique partnering opportunities in exploring new chemical spaces. The company combines access to the in-house produced screening compounds (4.7 million in stock) and building blocks (350,000 in stock) with a comprehensive platform of integrated discovery services in bioinformatics,

biology, and chemistry to advance and accelerate the efforts in drug discovery.

For more information, please visit: <https://enamine.net>

□□□□□□□ □□□□□□□□□□

□□□ □□□□□□□ □□□□□□□□□□□□:

Richard Edwards, PhD

Co-Founder & CTO

Email: rsedwards@nuclidetx.com

□□□ □□□□□□□:

Oleksii Gavrylenko

Director of Marketing

Email: o.gavrylenko@enamine.net

Oleksii Gavrylenko

Enamine Ltd

[email us here](#)

Visit us on social media:

[LinkedIn](#)

[Instagram](#)

[Facebook](#)

[X](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/902719482>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2026 Newsmatics Inc. All Right Reserved.